Research Article

The Role of Genetic Variation Near Interferon-Kappa in Systemic Lupus Erythematosus

Table 2

Clinical and serologic data for the SLE patients in each ancestral background.

African-AmericanEuropeanAsian
NoYesTotalNoYesTotalNoYesTotal

Renal0.530.475070.720.2810690.540.46674
Malar rash0.630.375080.440.5610680.560.44674
Discoid rash0.760.245080.890.1110690.920.08674
Photosensitivity0.630.375070.340.6610690.660.34674
Arthritis0.240.765080.180.8210690.380.62674
Oral ulcers0.760.245080.530.4710690.620.38674
Serositis0.480.524480.570.4310250.720.28673
Neurologic0.870.135080.890.1110690.930.07674
Hematologic0.280.725080.390.617780.150.85674
Immunologic0.130.875050.260.7410640.001.00674
ANA0.010.995080.030.9710690.001.00674
Anti-Ro0.710.294750.800.206550.660.34659
Anti-La0.910.094750.920.086610.920.08659
Anti-Sm0.840.163840.980.025860.900.1040
Anti-nRNP0.620.383840.920.085860.650.3540
Anti-Ribosomal P0.980.023840.990.015860.950.0540

“No” indicates the proportion of subjects lacking the clinical feature, and “Yes” is the proportion of subjects in whom that feature is present. Total indicates the total number of subjects for whom data is available. The first 11 rows are parameters assessed according to the American College of Rheumatology criteria for SLE [2], while the five rows which begin with “Anti-” indicate particular SLE-associated autoantibody specificities. ANA: anti-nuclear antibody.